

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 2003/088897 A3

(51) International Patent Classification⁷: **A61K 31/4439**,
31/4436, 31/443, 31/437, 31/44, C07D 401/12, 405/12,
409/12, 471/04, 213/72

N. [US/US]; 709 Swedeland Road, King of Prussia, PA
19406 (US).

(21) International Application Number:
PCT/US2002/010332

(74) Agent: **TAFT, Kingsley, L.**; Foley Hoag LLP, 155 Seaport
Boulevard, Boston, MA 02210-2698 (US).

(22) International Filing Date: 3 April 2002 (03.04.2002)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/282,225 6 April 2001 (06.04.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
AFFINIUM PHARMACEUTICALS, INC. [CA/CA];
100 University Avenue, 10th Floor, South Tower, Toronto,
Ontario M5J 1V6 (CA).

(72) Inventors; and

Published:

(75) Inventors/Applicants (*for US only*): **BURGESS, Walter, J.** [US/US]; 1250 South Collegeville Road, Collegeville,
PA 19426 (US). **JAKAS, Dalia** [US/US]; 1250 South
Collegeville Road, Collegeville, PA 19426 (US). **HUFF-
MAN, William, F.** [US/US]; 709 Swedeland Road, King
of Prussia, PA 19406 (US). **MILLER, William, H.**
[US/US]; 1250 South Collegeville Road, Collegeville,
PA 19426 (US). **NEWLANDER, Kenneth, A.** [US/US];
709 Swedeland Road, King of Prussia, PA 19426 (US).
SEEFELD, Mark, A. [US/US]; 1250 South Collegeville
Road, Collegeville, PA 19426 (US). **UZINSKAS, Irene,**

— *with international search report*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

(88) Date of publication of the international search report:
9 June 2005

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: FAB I INHIBITORS

(57) Abstract: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.



WO 2003/088897 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/10332

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/4439, 31/4436, 31/443, 31/437, 31/44 ; C07D 401/12, 405/12, 409/12, 471/04, 213/72
US CL : 514/300, 338, 339, 352 ; 546/113, 277.4, 280.4, 284.1, 312

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/300, 338, 339, 352 ; 546/113, 277.4, 280.4, 284.1, 312

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN STRUCTURE SEARCH, FILE CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 01/27103 A1 (SMITHKLINE BEECHAM CORPORATION) 19 April 2001 (19.04.2001), claims 1-5, 7, 9-11, 13-16.	1, 2, 4-8

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

19 November 2004 (19.11.2004)

Date of mailing of the international search report

20 APR 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Cecilia Tsang

Telephone No. (703)308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/10332

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
were not searched because they are improperly multiple dependent as covered by the second and third sentences of PCT rule 6.4(a).
3. ☒ Claim Nos.: 9 and 10
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
 2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
 3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
 4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: In Part 1, 2, 4-8
- Remark on Protest** ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

I. Compounds of formulae (I) or (II) where R3 represents monocyclic 6-membered ring containing only one N atom as heteroatom, pharmaceutical compositions containing these compounds and a method of using these compounds.

II. Compounds of formulae (I) or (II) where R3 represents bicyclic ring containing 2-3 N atoms as heteroatoms, pharmaceutical compositions containing these compounds and a method of using these compounds.

III. Compounds of formula (II) where R3 represents monocyclic 6-membered aryl ring, pharmaceutical compositions containing these compounds and a method of using these compounds.

IV. Compounds of formula (II) where R3 represents monocyclic 6-membered ring containing two N atoms as heteroatoms, pharmaceutical compositions containing these compounds and a method of using these compounds.

V. Compounds of formula (III), pharmaceutical compositions containing these compounds and a method of using these compounds.

The claims are deemed to correspond to the species listed above in the following manner:

Species I, II : Claims 1 and 2

Species III : Claim 2

Species V : Claim 3

The following claim(s) are generic: 4-8.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

There is no common core which in the Markush Practice, is a significant structural element shared by all of the alternatives; see PCT Administrative Instructions Annex B Part I (f) (i) (B) (1).